Dashboard
Manage Tickers

CELC Celcuity Inc.

Nasdaq celcuity.com


$ 45.80 $ -1.21 (-2.55 %)    

Tuesday, 14-Oct-2025 16:02:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.07 $ 0.00 (0 %)
DIA $ 464.16 $ 0.00 (0 %)
SPY $ 665.39 $ 0.00 (0 %)
TLT $ 91.00 $ 0.00 (0 %)
GLD $ 387.83 $ 0.00 (0 %)
$ 46.2
$ 46.96
$ 46.01 x 100
$ 50.37 x 12
-- - --
$ 7.58 - $ 63.06
818,767
na
1.96B
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 02-16-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-13-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
31 03-15-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-celcuity-maintains-70-price-target
Needham Reiterates Buy on Celcuity, Mainta...
10/03/2025 10:38:42

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

celcuity-to-present-phase-3-viktoria-1-breast-cancer-data-in-late-breaking-oral-session-at-esmo-2025
Celcuity To Present Phase 3 VIKTORIA-1 Bre...
09/22/2025 13:17:34

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

guggenheim-initiates-coverage-on-celcuity-with-buy-rating-announces-price-target-of-110
Guggenheim Initiates Coverage On Celcuity ...
09/22/2025 10:57:45

Guggenheim analyst Brad Canino initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of ...

celcuitys-nda-for-gedatolisib-in-hrher2--breast-cancer-accepted-into-fdas-real-time-oncology-review-program
Celcuity's NDA For Gedatolisib In HR+/HER2...
08/27/2025 20:14:22

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

hc-wainwright--co-maintains-buy-on-celcuity-raises-price-target-to-66
HC Wainwright & Co. Maintains Buy on Celcu...
08/18/2025 10:34:59

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

needham-maintains-buy-on-celcuity-lowers-price-target-to-70
Needham Maintains Buy on Celcuity, Lowers ...
08/15/2025 10:05:13

Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $74 to $70.

celcuity-q2-adj-eps-093-misses-088-estimate
Celcuity Q2 Adj. EPS $(0.93) Misses $(0.88...
08/14/2025 20:03:43

Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.88) by...

Core News & Articles
Earnings Scheduled For August 14, 2025
08/14/2025 08:32:32

insights-into-celcuitys-upcoming-earnings
Insights into Celcuity's Upcoming Earnings
08/13/2025 14:02:18

celcuity-prices-175m-in-2750-convertible-notes-and-common-stock-at-38-per-share-to-raise-2487m-for-oncology-pipeline
Celcuity Prices $175M In 2.750% Convertibl...
07/30/2025 10:38:25

leerink-partners-maintains-outperform-on-celcuity-raises-price-target-to-60
Leerink Partners Maintains Outperform on C...
07/28/2025 21:14:34

Leerink Partners analyst Andrew Berens maintains Celcuity (NASDAQ:CELC) with a Outperform and raises the price target from $...

hc-wainwright--co-maintains-buy-on-celcuity-raises-price-target-to-50
HC Wainwright & Co. Maintains Buy on Celcu...
07/28/2025 17:07:08

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
07/28/2025 17:06:06

crude-oil-gains-2-cea-industries-shares-spike-higher
Crude Oil Gains 2%; CEA Industries Shares ...
07/28/2025 16:05:27

alerus-financial-posts-better-than-expected-earnings-joins-celcuity-ses-ai-abercrombie--fitch-and-other-big-stocks-moving-higher-on-monday
Alerus Financial Posts Better-Than-Expecte...
07/28/2025 14:29:13

us-stocks-mixed-enterprise-products-partners-posts-upbeat-earnings
US Stocks Mixed; Enterprise Products Partn...
07/28/2025 14:03:41

celcuity-stock-skyrockets-on-breakthrough-trial-data-for-heavily-pretreated-breast-cancer
Celcuity Stock Skyrockets On Breakthrough ...
07/28/2025 13:42:36

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected in...

needham-reiterates-buy-on-celcuity-maintains-29-price-target
Needham Reiterates Buy on Celcuity, Mainta...
07/28/2025 12:16:04

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $29 price target.

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
07/28/2025 12:08:27

Core News & Articles
Market-Moving News for July 28th
07/28/2025 11:36:15

CELC: 133% | Celcuity Released Topline Results From PIK3CA Wild-Type Cohort Of Phase 3 VIKTORIA-1 Trial Of Gedatolisib Plus Ful...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION